OMOLARA FYLE THORPE: Open Payments
NPI 1578532065 · FLORISSANT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$614 in 5 payments from 5 companies in 2025. Trend: 2023 $433 · 2024 $626 · 2025 $614
Food & beverage: $614
| Company | Payments | Amount |
|---|---|---|
| SCPHARMACEUTICALS INC. | 1 | $150 |
| Astellas Pharma US Inc | 1 | $129 |
| Gilead Sciences, Inc. | 1 | $122 |
| Kowa Pharmaceuticals America, Inc. | 1 | $120 |
| Neurocrine BioSciences, Inc. | 1 | $94 |
Products named: FUROSCIX, Veozah, Descovy, ZORYVE, INGREZZA.
Industry payments across MO — which companies pay providers there.
